Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?

ABSTRACT:

Background

Triple negative breast carcinomas (TNBC) do not benefit from hormonal or Herceptin therapies. In search of novel therapeutic targets for TNBC, interest is escalating in a subset of these tumors that are androgen receptor (AR) positive with potential benefit from anti-androgen therapy. Against this background, the frequency of AR expression alone and in combination with other markers and morphologic features was assessed to identify TNBC subtypes for targeted therapy.

Methods

400 consecutive invasive mammary carcinomas with known estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR) and HER2 status were selected for study. The frequency of AR positivity alone or in combination with other markers was recorded with specific attention to the morph

SUBMITTER: Safarpour D 

PROVIDER: S-EPMC4106653 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature